1d
Clinical Trials Arena on MSNBiogen begins dosing in trial of felzartamab for kidney transplant patients with AMRIn Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...
February 2024 saw Cisco sign a 15-year vPPA to offtake from a 37MW solar farm in Spain developed by IGNIS. The farm is set to ...
Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
X-ELIO, a global leader in the renewable energy sector, and the Net Zero Consortium for Buyers (NZCB) have announced the ...
Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results